Navigation Links
The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
Date:3/8/2010

SEOUL, March 9, 2010 /PRNewswire/ -- PDVI (Pediatric Dengue Vaccine Initiative), a program of the International Vaccine Institute (IVI) funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide. Breaking news articles from reliable sources are displayed on a world map according to the location of dengue outbreaks. Dengue fever is endemic in over 100 countries and puts at risk half of the world's population.

"Denguewatch.org is an important public health tool providing instant access to news regarding dengue fever epidemics and their impact on global health," said Dr. John Clemens, IVI Director General, and PDVI Acting Director. "We believe that news reports about dengue hot spots and other important developments can help public health officials track the spread and understand the growing importance of this disease."

Denguewatch.org reports worldwide news alerts provided by Healthmap.org, a freely available Web site. HealthMap is a system based at Children's Hospital Boston, Massachusetts in collaboration with Harvard Medical School, MIT Media Lab and the Harvard-MIT Division of Health Sciences and Technology which integrates outbreak data of varying reliability, ranging from news sources (such as Google News) to curated personal accounts (such as ProMED) to validated official alerts (such as World Health Organization). Dengue news is aggregated and displayed by location for user-friendly access to the original alert.

"The Internet has become a critical medium for clinicians, public health practitioners, and the public seeking health information," said John S. Brownstein, Ph.D., co-founder of Healthmap.org with Clark Freifeld, "We are proud to collaborate with PDVI for http://www.denguewatch.org and we believe it can help foster surveillance and prevention of dengue fever worldwide."

Dengue: a global health threat

Dengue fever is a mosquito-borne disease caused by four types of dengue viruses (type 1 to 4). Overall, the disease is a potential threat for almost half of the world's population. Of the estimated 230 million people infected annually, two million, mostly children, develop dengue hemorrhagic fever (DHF), a severe form of the disease[1]. DHF is a leading cause of hospitalization, placing tremendous pressure on strained medical resources.

Dengue fever occurs mostly in tropical and subtropical countries in Asia and Latin America and is spreading to new parts of the globe each year. In addition, dengue affects countries such as Australia (Queensland) and the United States (Puerto Rico, Texas-Mexico border, Hawaii and the US-affiliated Pacific Islands). A substantial number of people travelling to endemic regions are also infected each year.

Expansion of dengue fever is driven by increased movement of people[2], massive unplanned urbanization, added to a lack of effective mosquito control[3]. Dengue prevention requires fostering a thorough knowledge of the disease.

About PDVI

The Pediatric Dengue Vaccine Initiative, a program of the International Vaccine Institute (IVI) founded in 2001, aims to reduce the burden of dengue disease by accelerating the development, evaluation and introduction of affordable dengue vaccines. PDVI works with public and private partners to accelerate the development and introduction of a dengue vaccine that is safe, effective and affordable for children in endemic countries. PDVI is funded by the Bill & Melinda Gates Foundation. For more information, please visit our website: http://www.pdvi.org

About the IVI

The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines for the world's poorest people, especially children in developing countries. Established as an initiative of the United Nations Development Program in 1997, the IVI operates under a treaty signed by 40 countries and the World Health Organization. IVI conducts research in more than 20 countries in Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, Japanese encephalitis, dengue fever and more. For further information, please visit: http://www.ivi.int

---------------------------------

[1] Beatty M Letson GW Margolis HS, Estimating the global burden of dengue., Am J Trop Med Hygiene 81, 5 :231 2009

[2] Mackenzie JS, Gubler DJ, Petersen LR. Nat Med 2004 Dec; 10 (12 Supll) :S98-109

[3] Mackenzie JS, Gubler DJ, Petersen LR. Nat Med 2004 Dec; 10 (12 Supll) :S98-109

SOURCE Pediatric Dengue Vaccine Initiative (PDVI)

Back to top
'/>"/>
SOURCE Pediatric Dengue Vaccine Initiative (PDVI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Pediatric Home Service (PHS) Named Quality Respiratory Care Provider
2. Sponsors for the 2010 Pediatric Cancer Research Foundation “Reaching for the Cure” Annual Cinco de Mayo Run/Walk Fundraising Event
3. NIH grant will create behavioral health registry for pediatric inflammatory bowel disease
4. Pediatricians Want Redesign of Hot Dogs, Candy to Curb Kids Choking
5. MCG to conduct first FDA-approved stem cell trial in pediatric cerebral palsy
6. Researchers discover new way to kill pediatric brain tumors
7. Possible pharmacological target(s) identified in pediatric OSA
8. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
9. Child-specific doses for pediatric PET patients
10. Minimally invasive adult liver donation for pediatric transplantation available exclusively
11. Improved air quality linked to fewer pediatric ear infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology: